Ionis Pharmaceuticals saw the highest growth of 1.74% in patent filings in May and 0.86% in grants in April in Q2 2024. Compared to Q1 2024, Q2 2024 saw an increase in patent filings by 0.61% and grants by 0.86%. GlobalData’s DataBook provides a comprehensive analysis of Ionis Pharmaceuticals‘s patent filings and grants. Buy the databook here.
Ionis Pharmaceuticals has been focused on protecting inventions in United States(US) with 16 publications in Q2 2024
The United States(US) Patent Office dominates the patent filings and grants with nearly 37% filings and 38% grants. The United States(US), European Patent Office(EPO), Israel(IL), and South Korea(KR) patent Office are among the top ten patent offices where Ionis Pharmaceuticals is filings its patents. Among the top granted patent authorities, Ionis Pharmaceuticals has 38% of its grants in United States(US), 31% in China(CN) and 15% in European Patent Office(EPO).
Arrowhead Pharmaceuticals and Roche could be the strongest competitors for Ionis Pharmaceuticals
Patents related to rare diseases and addiction lead Ionis Pharmaceuticals's portfolio
Ionis Pharmaceuticals has the highest number of patents in rare diseases followed by, addiction and climate change. For rare diseases, nearly 89% of patents were filed and 83% of patents were granted in Q2 2024.
Epilepsy related patents lead Ionis Pharmaceuticals portfolio followed by ataxia, and non-alcoholic steatohepatitis (nash)
Ionis Pharmaceuticals has highest number of patents in epilepsy followed by ataxia, non-alcoholic steatohepatitis (nash), seizures, and liver diseases.
For comprehensive analysis of Ionis Pharmaceuticals's filings and grants, buy the databook here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.